CCM
FATE icon

Coldstream Capital Management’s Fate Therapeutics FATE Stock Holding History

Coldstream Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-686
Closed -$542 – 1839
2025
Q1 		$542 Buy
+686
New +$841 ﹤0.01% 3330

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Coldstream Capital Management's FATE Position: Q2 2025 in Review

Coldstream Capital Management sold out of Fate Therapeutics (FATE) in Q2 2025, closing a stake of 686 shares — an estimated $542 sold.

Coldstream Capital Management first reported a position in FATE in Q1 2025 and held it in 1 quarter. The position peaked at $542 in Q1 2025. 139 funds tracked by Wall St. Rank hold FATE as of Q2 2025.

  • Coldstream Capital Management reported no remaining Fate Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 686 Fate Therapeutics shares in Q2 2025, an estimated $542.
  • Coldstream Capital Management first reported a position in Fate Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Fate Therapeutics position peaked at $542 in Q1 2025.
  • 139 funds tracked by Wall St. Rank held Fate Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.